Skip to main content

Table 1 Baseline characteristics of the 150 patients treated with or without prednisolone

From: Impact of low-dose prednisolone on bone synthesis and resorption in early rheumatoid arthritis: experiences from a two-year randomized study

  Prednisolone n = 70 No prednisolone n = 80 p level
Age, years 51.3(48.2 to 54.4) 58.4 (55.6 to 61.2) 0.001
Disease duration, months 6.3 (5.5 to 7.1) 5.7 (5.1 to 6.4) 0.27
Women, % 69 65 0.64
Menopause, % 50 69 0.05
Menopause age, years* 50(48 to 51) 50(47 to 52) 0.97
Current or previous smoker, % 67 56 0.13
BMI*, kg/m2 24.3 (22.5 to 27.0) 25.6 (23.5 to 29.1) 0.07
RF positivity, % 66 55 0.25
Erosive disease, % 53 56 0.68
DAS28 5.2 (4.9 to 5.5) 5.5 (5.3 to 5.7) 0.12
ESR 39(33 to 44) 39(33 to 45) 0.96
CRP* 22(10 to 45) 21(10 to 58) 0.50
IL-6* 9.9(8.0 to 19.4) 11.7(9.2 to 27.6) 0.44
HAQ 1.0 (0.9 to 1.2) 1.0 (0.8 to 1.1) 0.52
Z-score, L2–L4* 0.36 (-0.24 to 0.88) 0.50 (-0.36 to 1.37) 0.29
Z-score neck* 0.01 (-0.56 to 1.00) -0.02 (-0.52 to 0.69) 0.87
P1NP*, μg/L 38.3 (28.0 to 51.8) 40.8 (28.8 to 57.0) 0.50
CTX-1*, ng/mL 0.26 (0.20 to 0.35) 0.33 (0.19 to 0.42) 0.17
1CTP* μg/L 4.5 (3.5 to 5.7) 4.2 (3.4 to 6.4) 0.62
IGF-1, μg/L* 173 (135 to 202) 210 (185 to 250) 0.34
IGFSD 0.15 (-0.06 to 0.6) 1.0 (0.4 to 1.6) 0.42
  1. Data presented as mean (95% confidence interval) or median (interquartile range).
  2. * depending on its distribution.
  3. BMI = body mass index; CRP = C-reactive protein; 1CTP = C-terminal propeptide of type I collagen; CTX-1 = C-terminal telopeptide of type I collagen; DAS = disease activity score; ESR = erythrocyte sedimentation rate; HAQ = health assessment questionnaire; IGF-1 = insulin-like growth factor 1; IGFSD = IGF-1, standard deviation-scores; IL-6 = interleukin-6; P1NP = Procollagen type I N-terminal propeptide; RF = rheumatoid factor. Bold p values are statistically significant.